Praxis Precision Medicines announced a proposed public offering of its common stock. Piper Sandler and Truist Securities will act as the joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRAX:
- Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering
- Praxis Precision Medicines, Inc. Announces Proposed Public Offering
- Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
- Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results